← Trials/Trial dossier/NCT00069849

TerminatedPhase 2

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Lead sponsor

Abbott

Asset

ABT-089

Listed sites

Recruiting sites

Enrollment

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•MMSE 10-26•Study partner/caregiver required

Primary endpoint

•Mini-Mental State Examination (MMSE)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDM03-614

NCT IDNCT00069849

Timeline

Milestones

Study start2003-07 (month precision)

Study first posted2003-10-02estimated

Last update posted2006-09-04estimated

Assets

Drug assets

ABT-089

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age85 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Current diagnosis of probable Alzheimer's disease.

•ADAS-cog score of at least 12 and MMSE score of 10 to 26.

•Non-smoker

•Must have legally authorized representative and a reliable caregiver. The caregiver and legally authorized representative may be the same person.

•Fluent in English

Exclusion criteria

•Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in the last 6 weeks.

•Has clinically significant or uncontrolled medical condition other than Alzheimer's disease.

•Nursing home resident.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Global cognition

1 endpoint

Primary/protocol endpoint

MMSE

Mini-Mental State Examination (MMSE)

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.